• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. ESTABLISHMENT AND VALIDATION OF ALPH-Q SCORE TO PREDICT MORTALITY RISK IN PATIENTS WITH ACUTE-ON-CHR

ESTABLISHMENT AND VALIDATION OF ALPH-Q SCORE TO PREDICT MORTALITY RISK IN PATIENTS WITH ACUTE-ON-CHR

来源 :2014年APASL专题会议暨第四届乙型病毒性肝炎专题会议 | 被引量 : 0次 | 上传用户：ISE7ENAK
【摘 要】
：
Background:There are no strong and powerful models in predicting the outcome of acute-on-chronic hepatitis B liver failure(ACHBLF).Here,we aimed to establish and validate a new prognostic score,named
【作 者】
：
Minghua Zheng Shengjie Wu Huadong Yan Zaixing Zheng Keqing Shi Faling Wu Yaoyao Xie Yuchen Fan Bozhi Ye Weijian Huang Yongping Chen 
【机 构】
：
Department of Infection and Liver Diseases,Liver Research Center,the First Affiliated Hospital of We
【出 处】
：
2014年APASL专题会议暨第四届乙型病毒性肝炎专题会议
【发表日期】
：
2014年4期
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background:There are no strong and powerful models in predicting the outcome of acute-on-chronic hepatitis B liver failure(ACHBLF).Here,we aimed to establish and validate a new prognostic score,named ALPH-Q that integrated electrocardiography parameters,to predict short-term mortality of patients with ACHBLF.
其他文献
The safety and therapeutic efficacy evaluation for UCMSCs transplantation combined with plasma excha
Background:Although previous studies showed that MSCs was a novel and promising treatment method and plasma exchange was also an effective therapy method for liver failure,there were still many proble
会议
Preserved function of circulating invariant natural killer T cells in patients with chronic hepatiti
Background:To date,the role of invariant natural killer T(iNKT) cells in chronic hepatitis B virus(HBV) infection is not fully understood.In previous reports,iNKT cells were identified by indirect met
会议
Identification of BST-2/tetherin-induced hepatitis B virus restriction and hepatocyte-specific BST-2
Background:Hepatitis B virus(HBV) is a major cause of liver disease which belongs to the Hepadnaviridae family of enveloped DNA viruses.BST-2/tetherin is an interferon-inducible antiviral protein that
会议
Impaired Antibody-Dependent Cellular Cytotoxicity Activity of Natural Killer Cells in Chronic HBV in
Background:Natural Killer(NK) cells are a key player in the innate immunity towards virus infection.However,NK phenotype and functional characteristics during chronic HBV infection are largely controv
会议
The Influence of Concomitant Nonalcoholic Fatty Liver Disease on Fibrosis Severity in Patients with
Background:To identify the impact of concomitant nonalcoholic fatty liver disease(NAFLD) on the development of hepatic fibrosis in patients with chronic hepatitis B(CHB).
会议
Detailed Structural Quantification of Hepatic Cirrhosis Progression
Background:Details in change of fibrosis structure in progressive cirrhosis is still unavailable.Taking advantage of qFibrosis tool,the present study aims to address this issue for understanding the p
会议
COMPARATIVE STUDY OF TELBIVUDINE AND PEGYLATED INTERFERON α-2a OPTIMIZATION THERAPY FOR E ANTIGEN-PO
Background:Aim To observe and compare the efficacy of telbivudine and pegalated interferon α-2a optimized therapy for E antigen-positive chronic hepatitis B patients.
会议
Low prevalence of Hepatitis B virus infection in patients with autoimmune diseases in a Chinese pati
Background:Hepatitis B is a very common communicable disease in China but the prevalence of hepatitis B virus(HBV) infection in patients with autoimmune diseases is unknown.We retrospectively investig
会议
The effect of complemental Ganshuang granule for improving liver fibrosis markers in patients with c
Background:To observe the ability of Ganshuang granules to improve markers of liver fibrosis when provided as supplemental therapy in patients with chronic hepatitis B(CHB) who achieved complete virol
会议
A NOVEL IMMUNOTHERAPY APPROACH WITH MULTIPLE TUMOR ANTIGENS ACTIVATED AUTOLOGOUS T CELLS IN HBV RELA
Background:Hepatocellular carcinoma(HCC) in China frequently occurs in the patients with chronic hepatitis B virus(HBV) infection.Here we present a novel approach(Smart T) of adoptive immunotherapy to
会议